乌帕替尼治疗中重度特应性皮炎患者的疗效与安全性:Measure Up 1和Measure Up 2随机临床试验随访数据分析
该分析基于两项正在进行的双盲、安慰剂对照、重复3期随机临床试验(Measure Up 1和Measure Up 2),评估乌帕替尼15 mg或30 mg每日一次口服治疗中重度特应性皮炎成人及青少年的52周疗效与安全性。第16周疗效维持至第52周,两种剂量耐受性良好且未发现新安全性信号,治疗因不良事件停药总体较低但30 mg剂量略高。
要点
- 第52周时,继续15 mg剂量组在Measure Up 1和Measure Up 2中分别有82.0%和79.1%达EASI 75。
- 第52周时,继续30 mg剂量组在两项研究中分别有84.9%和84.3%达EASI 75。
- 因不良事件停药总体较低,但30 mg剂量略高;两种剂量均耐受良好且无新安全性信号。
核心结论
- 在中重度特应性皮炎青少年和成人中,乌帕替尼15 mg或30 mg每日一次口服治疗至52周显示出有利的获益-风险特征,疗效应答持续。
研究设计与样本
- Measure Up 1和Measure Up 2为正在进行的双盲、安慰剂对照、重复3期随机临床试验,分别纳入151个和154个中心的成人和青少年中重度特应性皮炎患者。
- 患者按1:1:1随机接受每日一次口服乌帕替尼15 mg、30 mg或安慰剂;第16周时,基线随机接受乌帕替尼15 mg(Measure Up 1和Measure Up 2分别为273例和260例)和30 mg(分别为270例和268例)的患者继续原治疗,安慰剂组患者以双盲方式按1:1重新随机接受乌帕替尼15 mg(分别为121例和120例)或30 mg(分别为123例和121例)。
- 分析截止日期为2020年12月21日(Measure Up 1)和2021年1月15日(Measure Up 2)。
- 两项研究共纳入1609例患者,平均(SD)年龄33.8(15.6)岁,女性727例(45.2%),男性882例(54.8%)。
主要发现
- 第16周疗效维持至第52周。
- 第52周时,Measure Up 1和Measure Up 2中继续15 mg剂量组分别有82.0%(95% CI,77.0%-86.9%)和79.1%(95% CI,73.9%-84.4%)的患者达到EASI 75。
- 第52周时,Measure Up 1和Measure Up 2中继续30 mg剂量组分别有84.9%(95% CI,80.3%-89.5%)和84.3%(95% CI,79.6%-89.0%)的患者达到EASI 75。
- 第52周时,Measure Up 1和Measure Up 2中分别有59.2%(95% CI,52.9%-65.5%)和52.6%(95% CI,46.2%-59.1%)以及62.5%(95% CI,56.3%-68.7%)和65.1%(95% CI,58.9%-71.2%)的患者达到vIGA-AD评分0分(清除)或1分(几乎清除)且改善≥2级。
- 因不良事件停药总体较低,但30 mg剂量略高;两种剂量均耐受良好,未发现新安全性信号。
关键数值与推荐
- 第52周EASI 75应答率:继续15 mg组在Measure Up 1为82.0%(95% CI,77.0%-86.9%),在Measure Up 2为79.1%(95% CI,73.9%-84.4%)。
- 第52周EASI 75应答率:继续30 mg组在Measure Up 1为84.9%(95% CI,80.3%-89.5%),在Measure Up 2为84.3%(95% CI,79.6%-89.0%)。
- 第52周vIGA-AD 0/1且改善≥2级应答率:继续15 mg组在Measure Up 1为59.2%(95% CI,52.9%-65.5%),在Measure Up 2为52.6%(95% CI,46.2%-59.1%)。
- 第52周vIGA-AD 0/1且改善≥2级应答率:继续30 mg组在Measure Up 1为62.5%(95% CI,56.3%-68.7%),在Measure Up 2为65.1%(95% CI,58.9%-71.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Primary results from the Measure Up 1 and Measure Up 2 studies demonstrated upadacitinib efficacy and safety through 16 weeks in patients with atopic dermatitis. Longer-term outcomes remain unknown. OBJECTIVE: To evaluate long-term (52 weeks) efficacy and safety of upadacitinib treatment in patients with atopic dermatitis. DESIGN, SETTING, AND PARTICIPANTS: Measure Up 1 and Measure Up 2 are ongoing double-blind, placebo-controlled, replicate phase 3 randomized clinical trials that include adults and adolescents with moderate to severe atopic dermatitis at 151 and 154 centers, respectively. Cutoffs for this analysis were December 21, 2020 (Measure Up 1), and January 15, 2021 (Measure Up 2). INTERVENTIONS: Patients were randomized 1:1:1 to receive once-daily oral upadacitinib 15 mg, 30 mg, or placebo. At week 16, patients randomized at baseline to receive upadacitinib 15 mg (273 and 260 patients in Measure Up 1 and Measure Up 2, respectively) and 30 mg (270 and 268 patients) continued assigned treatment; placebo-treated patients were rerandomized 1:1 to receive upadacitinib 15 mg (121 and 120 patients in Measure Up 1 and Measure Up 2, respectively) or 30 mg (123 and 121 patients) in a double-blinded manner. MAIN OUTCOMES AND MEASURES: Safety and efficacy, including 75% improvement in the Eczema Area and Severity Index and Validated Investigator Global Assessment for Atopic Dermatitis score of clear (0) or almost clear (1) with 2 or greater grades of improvement, were assessed. RESULTS: Measure Up 1 and Measure Up 2 included a total of 1609 patients (mean [SD] age, 33.8 [15.6] years; 727 women [45.2%]; 882 men [54.8%]). Efficacy at week 16 was maintained through week 52. At week 52, 75% improvement in the Eczema Area and Severity Index was achieved by 82.0% (95% CI, 77.0%-86.9%) and 79.1% (95% CI, 73.9%-84.4%) of patients continuing the 15-mg dose and 84.9% (95% CI, 80.3%-89.5%) and 84.3% (95% CI, 79.6%-89.0%) of patients continuing the 30-mg dose (for Measure Up 1 and Measure Up 2, respectively); Validated Investigator Global Assessment for Atopic Dermatitis score of clear (0) or almost clear (1) with 2 or greater grades of improvement was achieved by 59.2% (95% CI, 52.9%-65.5%) and 52.6% (95% CI, 46.2%-59.1%) and 62.5% (95% CI, 56.3%-68.7%) and 65.1% (95% CI, 58.9%-71.2%) of patients in the Measure Up 1 and Measure Up 2 studies, respectively. Treatment discontinuation due to adverse events was low overall but was slightly higher for the upadacitinib 30-mg dose. Both upadacitinib doses were well tolerated with no new safety signals. CONCLUSIONS AND RELEVANCE: In this analysis of follow-up data from 2 randomized clinical trials, longer-term treatment of adolescents and adults with moderate to severe atopic dermatitis with upadacitinib demonstrated a favorable benefit-risk profile, with sustained efficacy responses through 52 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03569293 (Measure Up 1) and NCT03607422 (Measure Up 2).
引用
- Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022. PMID: 35262646. doi:10.1001/jamadermatol.2022.0029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。